LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akcijų sąrašas・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

16.7 1.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.53

Max

16.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	117B 106B
Pardavimai	100B 1.2T
P/E Sektoriaus vid.	75.273 49.8
Pelnas, tenkantis vienai akcijai	0.21
Dividendų pajamingumas	3.98
Pelno marža	8.697
Darbuotojai	47,455
EBITDA	140B 456B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+26.81% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	3.98% 2.25%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-3B 52B
Ankstesnė atidarymo kaina	15.67
Ankstesnė uždarymo kaina	16.7

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

N/A / 15.16 Palaikymas ir pasipriešinimas

Takeda Pharmaceutical Co Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-29 07:11; UTC

Uždarbis

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

2025-12-19 03:32; UTC

Pagrindinės rinkos jėgos

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

2025-10-30 09:39; UTC

Uždarbis

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

2025-10-30 07:32; UTC

Uždarbis

Takeda Posts Quarterly Net Loss, Cuts Guidance

2025-10-21 15:33; UTC

Pagrindinės rinkos jėgos

Healwell AI Shares Rise on AI-Platform Demonstration

2026-01-29 06:53; UTC

Uždarbis

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

2026-01-29 06:36; UTC

Uždarbis

Takeda Raises FY Revenue, Net-Profit Views

2026-01-29 06:34; UTC

Uždarbis

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

2026-01-29 06:33; UTC

Uždarbis

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

2026-01-29 06:32; UTC

Uždarbis

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

2025-10-30 07:10; UTC

Uždarbis

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

2025-10-30 06:50; UTC

Uždarbis

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

2025-10-30 06:49; UTC

Uždarbis

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

2025-10-30 06:48; UTC

Uždarbis

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

2025-10-30 06:45; UTC

Uždarbis

Takeda: Lowered Guidance Reflects Impairment Charges Associated With Strategic Pipeline Decisions

2025-10-30 06:42; UTC

Uždarbis

Takeda Pharmaceutical Cuts FY Revenue, Net-Profit Views

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H Pretax Pft Y178.80B Vs Pft Y255.98B

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H EPS Y71.57 Vs EPS Y118.85

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H Oper Pft Y253.56B Vs Pft Y350.58B

2025-10-30 06:40; UTC

Uždarbis

Takeda Pharmaceutical 1H Rev Y2.22T Vs Y2.38T

2025-10-10 15:13; UTC

Įsigijimai, susijungimai, perėmimai

J&J, Protagonist Have Existing Ties -- WSJ

2025-10-10 15:13; UTC

Įsigijimai, susijungimai, perėmimai

Protagonist Has Market Value Over $4B -- WSJ

Akcijų palyginimas

Kainos pokytis

Takeda Pharmaceutical Co Ltd ADR Prognozė

Kainos tikslas

By TipRanks

26.81% į viršų

12 mėnesių prognozė

Vidutinis 21 USD 26.81%

Aukščiausias 21 USD

Žemiausias 21 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Takeda Pharmaceutical Co Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Takeda Pharmaceutical Co Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 15.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.